Abstract
This paper reviewed two common sources of elderly incontinence with brain etiologies, “vascular incontinence” (a disorder of bladder control resulting from cerebral white matter disease) and normal-pressure hydrocephalus (NPH), from a neurological point of view. Both diseases manifest with gait disturbance, dementia, and urinary incontinence. Urinary frequency/ urgency (overactive bladder, OAB) often precedes urinary incontinence in both diseases, and in some patients may be the initial manifestation. While NPH is less common than vascular incontinence, at approximately one-tenth the prevalence, it is important because the symptoms can be reversed by shunt surgery or endoscopic third ventriculostomy. For vascular incontinence, early identification of risk factors and initiation of secondary prevention are necessary. Detrusor overactivity due to frontal hypofunction may underlie the bladder disorder in both diseases. Treatment options for urinary incontinence include anticholinergics, which do not easily penetrate the blood-brain barrier, or newer drugs that act on the adrenergic beta-3 receptor and other receptors.
Keywords: Geriatric incontinence, white matter disease, normal-pressure hydrocephalus, overactive bladder, anticholinergic drug
Current Drug Therapy
Title:“Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Volume: 7 Issue: 1
Author(s): Ryuji Sakakibara, Jalesh Panicker, Clare J. Fowler, Fuyuki Tateno, Masahiko Kishi, Yohei Tsuyusaki, Tomoyuki Uchiyama and Tatsuya Yamamoto
Affiliation:
Keywords: Geriatric incontinence, white matter disease, normal-pressure hydrocephalus, overactive bladder, anticholinergic drug
Abstract: This paper reviewed two common sources of elderly incontinence with brain etiologies, “vascular incontinence” (a disorder of bladder control resulting from cerebral white matter disease) and normal-pressure hydrocephalus (NPH), from a neurological point of view. Both diseases manifest with gait disturbance, dementia, and urinary incontinence. Urinary frequency/ urgency (overactive bladder, OAB) often precedes urinary incontinence in both diseases, and in some patients may be the initial manifestation. While NPH is less common than vascular incontinence, at approximately one-tenth the prevalence, it is important because the symptoms can be reversed by shunt surgery or endoscopic third ventriculostomy. For vascular incontinence, early identification of risk factors and initiation of secondary prevention are necessary. Detrusor overactivity due to frontal hypofunction may underlie the bladder disorder in both diseases. Treatment options for urinary incontinence include anticholinergics, which do not easily penetrate the blood-brain barrier, or newer drugs that act on the adrenergic beta-3 receptor and other receptors.
Export Options
About this article
Cite this article as:
Sakakibara Ryuji, Panicker Jalesh, J. Fowler Clare, Tateno Fuyuki, Kishi Masahiko, Tsuyusaki Yohei, Uchiyama Tomoyuki and Yamamoto Tatsuya, “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies, Current Drug Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157488512800389218
DOI https://dx.doi.org/10.2174/157488512800389218 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents
Current Drug Targets MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Microdialysis in Drug Discovery
Current Drug Discovery Technologies How Could We Reduce Antibiotic Use in Critically Ill Patients?
Infectious Disorders - Drug Targets Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Anti-Infective Agents β-Adrenomimetic Actions in the Hypotension and Vasodilatation Induced by a Chromatographic Active Fraction from Bidens pilosa L. (Asteraceae) in Mammals
Current Bioactive Compounds The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Emerging Antimicrobial Applications of Nitric Oxide (NO) and NO-Releasing Materials
Anti-Infective Agents in Medicinal Chemistry Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design The Role of Insertion Allele of Angiotensin Converting Enzyme Gene in Higher Endurance Efficiency and Some Aspects of Pathophysiological and Drug Effects
Current Medicinal Chemistry Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends
Current Vascular Pharmacology Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism